Happy new year

Best wishes for 2019 from VALBIOTIS.

VALBIOTIS’ R&D Center

The Discovery and Preclinical Research Platform at Riom: a state-of-the-art GLP-standard infrastructure.

Intestinal microbiota

VALBIOTIS confirms its interest in the study of the intestinal microbiota.

VALEDIA®

Product developed for prediabetics.

1 4

S c r o l l

Products

.01

Pipeline

4 products in clinical development

Learn more

.02

VALEDIA® – Prediabetes

Prediabetes
• Reduction of the risk of type 2 diabetes
• Phase IIa clinical study ongoing

Learn more

.03

LpD64

Overweight and /or obesity
• Modulation of intestinal microbiota
• Clinical Phase I/II positive

Learn more

.04

VAL-070

Mild to moderate hypercholesterolemia
• Reduction of blood LDL-cholesterol
• Clinical Phase I/II positive

Learn more

.05

VALEDIA® – Non alcoholic fatty liver

Non-alcoholic fatty liver (NAFL)
• Reduction of NAFL, risk factor for NASH
• Clinical Phase I/II positive

Learn more

Key figures

Patent families filed

All exploitation rights obtained

Employees

> 35

75% in R&D

Listed on the Stock Exchange

2017

Euronext Growth

Our last posts

07.01.2019

J.P. Morgan Healthcare Conference

28.11.2018

Journées Francophones de Nutrition

09.11.2018

American Association for the Study of Liver Diseases Congress

09.10.2018

European Large & Midcap Event

Voir tous

Investors

Products

Pipeline

VALEDIA® – Prediabetes

LpD64

VAL-070

VALEDIA® – Non alcoholic fatty liver

Key figures

Patent families filed

Employees

Listed on the Stock Exchange

Our last posts

J.P. Morgan Healthcare Conference

Journées Francophones de Nutrition

American Association for the Study of Liver Diseases Congress

European Large & Midcap Event

VALBIOTIS© listed on the Stock Exchange